Cross-over, 2-sequence, 2-treatment, 2-period single-centre, phase IV, randomized, open label study.
Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Provision of informed consent form prior to any study specific procedures, sampling and analysis.
Individuals must be ≥ 18 years of age at the time of signing the informed consent
Individuals must have a confirmed diagnosis of Heart Failure (HF) according to clinical practice guidelines NYHA functional class I-III (with HFrEF or HFpEF).
Limited life expectancy (less than 1 year) based on investigator's clinical judgement.
Patients without indication of beginning treatment with Dapagliflozin according to the Data Sheets and Consumer Medicine Information.
Malignancy (with active treatment) or other life-threatening disease
Patients in whom proper study compliance cannot be guaranteed